Abstract: A method of enhancing the activity of water-soluble, low molecular weight polymeric dispersants used to suspend iron oxides in cooling waters which also contain soluble iron compounds comprises treating such waters with the water-soluble, low molecular weight polymeric dispersant and a water-soluble copolymer consisting of 25% by weight of acrylic acid and 75% by weight acrylamide with the ratio of copolymer to soluble iron being 1:1.
Abstract: A tumor suppressive composition active against lymphoma consisting of an injection of hybrid protein anti Thy 1.2 monoclonal antibody-ricin and hyperosmotic lactose. The inoculation i.v. of murine tissues in vivo by lymphoma is made at -20 to -25 days and the tumor suppressant composition is used i.v. at Day 1 in an amount of 1-3 .mu.g of anti Thy monoclonal antibody-ricin together with sufficient hyperosmotic lactose to raise the lactose level to 20-30 mM. The broad purpose of this invention is to modify the receptor specificity of a potent toxin such as ricin by coupling it with a monoclonal antibody directed at a specific tumor or differentiation antigen. The object here is to use the reagent to selectively kill tumor cells without affecting normal cells.
Type:
Grant
Filed:
September 30, 1980
Date of Patent:
November 16, 1982
Inventors:
David M. Neville, Jr., Richard J. Youle
Abstract: Specific method of irreversible antagonism of histamine receptors, especially H.sub.1 receptors, in, for example, isolated guinea pig vas deferens by 4(5)-[2-(4-azido-2-nitroanilino)ethyl]imidazole (AAH), which is a photoaffinity analog of histamine actuated unusually by light in the visible spectrum. Additionally, compounds of the present invention are represented by the formula ##STR1## wherein R.sub.1 and R.sub.2 represent an electron withdrawing group of the formula, H, --NO.sub.2, --Cl, --F, --Br, --I, --SO.sub.3 H. When two groups occur, it is not necessary that those groups be identical. In preferred compounds R.sub.1 is --NO.sub.2 and R.sub.2 is H and R.sub.1 is ortho to amine group.R.sub.3, R.sub.4, R.sub.5 and R.sub.6 represent a proton or lower alkyl of straight and branched carbon chains. In preferred compounds R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are protons or methyl groups with not more than two of the four positions substituted with an alkyl group. Preference is given for R.sub.4 and R.sub.5.
Type:
Grant
Filed:
May 22, 1981
Date of Patent:
November 2, 1982
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Jeffrey S. Fedan, John P. O'Donnell, G. Kurt Hogaboom
Abstract: The 5'-formate and the 5'-phosphate derivatives of 9-.beta.-D-arabinofuranosyl-2-fluoroadenine have been prepared as prodrug forms of the anti-cancer agent 9-.beta.-D-arabinofuranosyl-2-fluoroadenine, known as F-ara-A. These derivatives are quite water soluble whereas F-ara-A itself is sparingly soluble in water or in any organic solvents. Delivery of these prodrug forms to mice with L1210 leukemia results in the formation of higher levels of the triphosphate of F-ara-A, the active form of the drug, in the target L1210 leukemia cells. These prodrug forms are much more active chemotherapeutically than 9-.beta.-D-arabinofuranosyladenine, known as ara-A, and equivalent in activity to the combination of ara-A and 2'-deoxycoformycin, known as 2'-dCF, an effective in vivo inhibitor of adenosine deaminase, a ubiquitous enzyme that destroys ara-A in vivo.
Type:
Grant
Filed:
February 24, 1981
Date of Patent:
November 2, 1982
Assignee:
The United States of America as represented by the Department of health and Human Services
Abstract: In the detection of the highly transmittable agent of non-A, non-B hepatitis there is described a method utilizing antigen-antibody reaction and a preferred counterelectrophoresis method for the detection of said antigen. The method may be applied as in the recipients of blood transfusions and also may be applied to screening blood donors where the blood donor had transmitted by transfusion non-A, non-B hepatitis antigen several years previously or there was at least a 1-5 year retrospective period from donating blood to retention of active transmittable agent.
Type:
Grant
Filed:
May 21, 1979
Date of Patent:
October 26, 1982
Assignee:
Govt. of the U.S., as represented by the Secretary, Dept. of Health & Human Services
Abstract: A new reagent effective in inhibiting cholesterol synthesis 75% in human fibroblasts derived from patients suffering from the disease familial hypercholestrolemia is mannose-6-phosphate-low density lipoprotein and is effective in tissue culture test systems at 100 .mu.g/ml after a ten-hour exposure. The broad purpose of this invention is to modify the receptor specificity of a protein so that it will enter cells which were previously impermeable and exert new effects or reverse a pathological condition. Toxins may also be modified in this manner producing cell type specific and tumor suppressive reagents which are effective in a dose range of 0.3-3 .mu.g. The object here is to use the reagent to selectively kill one cell type which is exerting a pathological effect without affecting normal cells. Among others to which this invention is applicable are Man6P-low density lipoprotein, Man6P-ricin, Man6P-Modeccin, anti Thy 1.2 monoclonal antibody-ricin and anti Thy 1.1 monoclonal antibody-ricin.
Type:
Grant
Filed:
October 23, 1980
Date of Patent:
October 26, 1982
Assignee:
U.S. Govt., Dept. of Health & Human Services
Inventors:
David M. Neville, Jr., Richard J. Youle, Gary J. Murray
Abstract: A highly stable metal oxide oil slurry useful in reducing slag, facilitating removal of deposits from boiler tubes, and reducing corrosion on the heating surfaces of boilers has been developed. Such a slurry consists essentially of about 50% by weight magnesium oxide or the entity of magnesium oxide and alumina oxide, together with an oil-soluble emulsifier such as alkanolamide and preferably ethanolamide, or an alkanol with a carbon chain greater than a C.sub.3 alcohol, an oil-soluble dispersant such as a C.sub.12 -C.sub.22 entity selected from an unsaturated or saturated fatty acid; e.g., oleic acid. Also, as a constituent is an anionic surfactant such as magnesium lauryl sulfate in an oil base such as No. 2 fuel oil. The alkanolamide is fashioned from heating alkanolamines and fatty acids either in a 1:1 ratio or 2:1 ratio. The reactant amino alcohol is in the range C.sub.10 -C.sub.24. The alcohol itself is greater than C.sub.3 and up to C.sub.16, with a preferred range C.sub.12 -C.sub.16.
Type:
Grant
Filed:
January 19, 1981
Date of Patent:
October 19, 1982
Assignee:
Nalco Chemical Company
Inventors:
George T. Kekish, Mei-Jan L. Lin, John H. Collins
Abstract: A grommet for relieving tension or strain when securing a cable in an aperture comprising two generally circular in cross section, tubular rotatably and coaxially disposed telescoping clamping members with the inner cross section of the outer member deviating from the circular cross section and with the inner member being slotted at one of its ends, in an axial direction over part of its length to form clamping jaws having rising or tapering projections thereon disposed within said outer member and which cause the clamping jaws to engage and lock the cable when the members are rotated relative to each other.
Abstract: The utilization of hepatitis B immune globulin as a preparation for preventing transmission of the hepatitis B virus (HBV) by injectable biologics, by incubation of the injectable biologics and hepatitis B immune globulin together in vitro prior to administration to patient. The hepatitis B immune globulin is utilized in a dosage of 5 ml and in a preferred titer of 1 to 100,000. The titer may vary to a range of 1 to 100 concentration with an intermediate range of 1 to 1,000 ranging down to 1 to 100,000. Also there may be used other immune globulins such as immune serum globulin (ISG).
Type:
Grant
Filed:
April 11, 1980
Date of Patent:
August 24, 1982
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
David L. Aronson, Edward Tabor, Robert J. Gerety
Abstract: A high-lift attachment for a tractor provided with a three-point linkage comprises a platform provided with a vertical backing frame, and a vertical intermediate frame positioned between the backing frame and the tractor body. The intermediate frame is connected to the three-point linkage arms of equal length by three pivots which are positioned on this frame in spatial alignment corresponding to the position of the points of attachment on the tractor, whereby the frame remains in its vertical position at any height of lift. The intermediate frame and the backing frame are interconnected by one upper and two lower links which are in parallel alignment and wherein the distance between their linkage points is identical for all three links. The two lower links are elongated beyond the intermediate frame towards the tractor body which latter is provided with a pivoted member serving to attach the ends of these links and to keep them in their initial lowermost position.
Abstract: This invention relates to the production of 4a-aryldecahydroisoquinolines where the aryl group is selected as 3-methoxy phenyl and intermediates. These compounds are morphine analogs and show utility similar to the known morphine, codeine, and thebaine.
Type:
Grant
Filed:
January 14, 1981
Date of Patent:
August 24, 1982
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Henry Rapoport, Dwight D. Weller, Richard D. Gless
Abstract: This invention relates to a precursor or intermediate for a rotavirus vaccine to protect infants and young children against diarrhea caused by rotavirus. The invention is the efficient propagation of a strain of human rotavirus type 2 prepared by a method of cultivation by multiple passages in vivo in gnotobiotic piglets and by multiple passages in vitro subsequently in AGMK (African green monkey kidney) cell cultures. Additionally, rotavirus is treated with a biologically active amount of trypsin prior to growth in AGMK cells, and the inoculated cell cultures are centrifuged at a low centrifugal force before incubation.
Type:
Grant
Filed:
November 19, 1980
Date of Patent:
July 27, 1982
Assignee:
The United States of America as represented by the Secretary of the Department of Health & Human Services
Inventors:
Richard G. Wyatt, Walter D. James, Edward H. Bohl, Kenneth W. Theil, Linda J. Saif, Anthony R. Kalica, Harry B. Greenberg, Albert Z. Kapikian, Robert M. Chanock
Abstract: A method of bonding a material to a substrate utilizing a hydrogel adhesive and a source of microwave energy of at least 100 MHz through a waveguide. The bonding may be temporary and frangible by water or may be permanent where it is achieved in a pressure vessel.
Type:
Grant
Filed:
June 23, 1980
Date of Patent:
July 13, 1982
Assignee:
The United States of America as represented by the Secretary of the Department of Health & Human Services
Abstract: A domestic hair dryer comprises an axisymetrical casing of circular cross section, the rear part of which forms a tubular grip, housing an electric switch and cable connection. The front part of the casing is enlarged in the form of an ellipsoid or prolate spheroid with its front end cut off to form an air outlet. This front end also contains a connector for attaching a hollow hair brush. The spherical front part contains an electric motor with an axial fan impeller mounted on its shaft positioned so as to rotate in its widest portion. In front of the impeller a heating element is fastened inside the casing, which element is in the shape of a hollow cylindrical cage formed by air guide vanes; these are alternately connected at their opposite ends to form an electric circuit in zigzag shape. The cage is of an inner diameter similar to that of the air outlet and is fastened at its front end adjacent this outlet.
Abstract: A process for the production of tripdiolide, triptolide and celastrol comprises the steps of:(a) preparing a cellular inoculum from Tripterygium wilfordii Hook F;(b) inoculating a nutrient growth medium with the cellular inoculum and incubating the inoculated growth medium at 20.degree.-30.degree. C. for up to 8 weeks to produce a cellular product;(c) harvesting the cellular product from the inoculated growth medium; and(d) isolating tripdiolide, triptolide and celastrol from the cellular product and supernatant inoculated growth medium.
Type:
Grant
Filed:
July 2, 1980
Date of Patent:
May 4, 1982
Assignee:
The United States of America as represented by the Secretary of the Department of Health & Human Services
Inventors:
William T. Chalmers, James P. Kutney, Phillip J. Salisbury, Kenneth L. Stuart, Phillip M. Townsley, Brian R. Worth
Abstract: A method of synthesizing fused ring pyridines (annulated) by co-oligomerization of .alpha.,.omega.-diynes with about molar equivalents of nitriles using a Co.sup.+1 catalyst preferably cyclopentadienyl cobalt dicarbonyl. Additionally, new compounds of tricyclic quinolizine-4-ones were produced where excess cyanoacetic ester starting materials were utilized (about 2:1 equivalent nitriles:diyne). The results with the catalyst employed indicated a stepwise mechanism in which cobalt(I) catalyst first forms a metallocycle intermediate derived from the bisacetylene. This cobalt(III) intermediate reacts preferentially with nitriles to give the product annulated pyridines in good yield. Generally, preferred conditions indicated roughly molar equivalents of reactants with no substantial excess of either reactant for the bicyclic compounds.
Type:
Grant
Filed:
July 5, 1979
Date of Patent:
May 4, 1982
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: Disclosed is an intrauterine device contraceptive to avoid pregnancy.The device comprises a vector and contraceptor, said vector consisting of a vertical stem having two horizontal arms, the arm at the end of said vertical stem being longer than the second arm, said vertical stem being twisted by a copper wire having a surface area of above 200 square millimeters. The vertical stem is made from a plastic material, generally polyethylene.The present intrauterine device contraceptive has the advantage of a complete reduction of the expulsion in view of its new particular shape.
Abstract: A method of clinical diagnosis and a composition for detecting malignant lesions of the oral cavity by utilizing as a rinse, toluidine blue preferably in acetic solution of water and ethanol. A preferred rinse is 5 cc 1% toluidine blue solution which is utilized in 1% acetic acid and water. In the method the solution (5-10 cc) is poured into floor of mouth and patient is advised to rinse and gargle.
Type:
Grant
Filed:
December 19, 1979
Date of Patent:
March 23, 1982
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: This invention relates to a method of optimizing the usable content of geothermal fluids to make use of steam in the largely aqueous and heated fluid. These fluids contain non-condensable gases, such as H.sub.2 S and CO.sub.2, as well as small quantities of acid and B(OH).sub.3. The removal of the more troublesome and corrosive agents, H.sub.2 S and CO.sub.2, is expressed here by utilization of pH control in an evaporator or series of evaporators. At an acid or low pH (3 to 5) in the input side of an evaporator, the non-condensable gases are non-ionized and exert partial gas pressures, and in the input chamber they may be removed or separated from the condensable gases. In the condensate side of the evaporator where the pH is maintained in the alkaline range and preferably about 11, the H.sub.2 S and CO.sub.2 are ionized in solution as acids and acid salts and do not separate out as gases.
Abstract: A blood contacting layer and a blood contacting interface consisting of a solvent cast polyurethane alloyed with a filler-free silicone rubber. In the above, the alloy interface comprises an interpenetrating polymer network consisting of polyurethane and filler-free silicone rubber at the molecular level. The process or method of making the layer consists of preheating a metal mold such as an aluminum mold and filling it with a wax. After the wax form is removed, polished and cleaned, it is dipped first in a filler-free silicone rubber which is cured. It is then dipped in segmented polyurethane with curing of 150.degree. F. for about one hour to evaporate the polyurethane solvent. Multiple dips are utilized up to 5 or 7 for implementing the polyurethane. The form containing both silicone rubber and polyurethane is finally cured for a day or 24 hours at about 150.degree. F. and the wax form is removed.
Type:
Grant
Filed:
November 7, 1979
Date of Patent:
January 26, 1982
Assignee:
The United States of America as represented by the Department of Health & Human Services